Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Venous thromboembolism, that consists of the interrelated conditions deep-vein thrombosis
and pulmonary embolism, is an under-appreciated vascular disease. In Western regions …

In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Objectives Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis …

Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes
deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is …

Venous thromboembolism (VTE) is categorized by the US Surgeon General as a major
public health problem. VTE is relatively common and associated with reduced survival and …

Venous thromboembolism (VTE) includes deep vein thrombosis and pulmonary embolism,
and a combination of environmental and genetic risk factors contributes to VTE risk. Within …